Cerebral Therapeutics’ initial clinical program uses a specialized implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of a proprietary formulation of the anti-epileptic drug valproic acid, called CT001, for which Cerebral Therapeutics has an exclusive license agreement from the University of Colorado. An optimal dose of CT001 is delivered directly into the area of the brain responsible for seizure initiation and propagation. 

The Company reported preliminary clinical proof of concept data from an open-label Phase 1b/2a clinical trial demonstrating that epilepsy patients who failed multiple oral medications experienced a 50-90% reduction in seizure frequency and severity following implantation with Cerebral Therapeutics’ novel drug-device combo.